Compare VWAV & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VWAV | CRBU |
|---|---|---|
| Founded | 2024 | 2011 |
| Country | United States | United States |
| Employees | 12 | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.7M | 166.6M |
| IPO Year | N/A | 2021 |
| Metric | VWAV | CRBU |
|---|---|---|
| Price | $2.93 | $1.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.75 |
| AVG Volume (30 Days) | 562.1K | ★ 2.4M |
| Earning Date | 05-18-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.63 |
| Revenue Next Year | N/A | $10.93 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.13 | $1.38 |
| 52 Week High | $15.80 | $3.53 |
| Indicator | VWAV | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 30.82 | 35.14 |
| Support Level | N/A | $1.39 |
| Resistance Level | $6.64 | $1.73 |
| Average True Range (ATR) | 0.34 | 0.11 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 0.64 | 0.94 |
VisionWave Holdings Inc is a technology company focused on the development and commercialization of artificial intelligence (AI) and autonomous solutions across air, ground and sea environments. Through its subsidiary, the Company designs and deploys technologies including radars, radio frequency (RF) sensing, unmanned aerial and ground systems, remote weapon stations and active protection systems for defense, military, homeland security and industrial applications. Its proprietary AI engine supports autonomous decision-making and product lines at various stages of development and commercialization. Revenue is generated through product sales, technology licensing, strategic alliances and joint ventures, with products including C-UAS, multi-purpose autonomous UAS and Vision-AI technology.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.